Palvella Therapeutics (PVLA) director buys 4,000 shares in deal

Rhea-AI Filing Summary

Palvella Therapeutics director George M. Jenkins bought 4,000 shares of common stock at $125 per share in an underwritten offering that closed on February 27, 2026. This purchase, reported as an open-market or private transaction, increased his direct holdings to 187,171 shares. He also reports indirect ownership of 13,516 shares held by Eagles Mere Air Museum Foundation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JENKINS GEORGE M

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		P		4,000(1)	A	$125	187,171	D
Common Stock								13,516	I	By foundation(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock purchased in the underwritten offering of Palvella Therapeutics, Inc. at the offering price, which closed on February 27, 2026.

2. Eagles Mere Air Museum Foundation.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PVLA director George M. Jenkins report?

George M. Jenkins reported buying 4,000 shares of Palvella Therapeutics common stock. The shares were purchased in an underwritten offering at the offering price and are reported as an open-market or private transaction, increasing his disclosed direct holdings to 187,171 shares.

At what price did George M. Jenkins purchase PVLA shares?

He purchased the 4,000 Palvella Therapeutics shares at $125 per share. The transaction was part of an underwritten offering that closed on February 27, 2026, and is reported as a standard open-market or private purchase of common stock.

How many PVLA shares does George M. Jenkins own after this transaction?

After the purchase, George M. Jenkins directly holds 187,171 shares of Palvella Therapeutics common stock. The filing also shows indirect ownership of 13,516 additional shares held by Eagles Mere Air Museum Foundation, which is reported as foundation-held stock associated with him.

What indirect PVLA shareholdings are associated with George M. Jenkins?

The filing discloses 13,516 Palvella Therapeutics shares held indirectly "By foundation." A footnote identifies this entity as Eagles Mere Air Museum Foundation, indicating that these shares are reported as indirect ownership linked to Jenkins rather than as directly held stock.

Was the PVLA insider share purchase part of an offering?

Yes. A footnote states the 4,000 shares represent common stock purchased in an underwritten offering of Palvella Therapeutics at the offering price. The transaction closed on February 27, 2026, and is reported as a purchase of common stock by a company director.

Is the PVLA insider transaction a buy or sell by George M. Jenkins?

The transaction is a buy. The Form 4 characterizes it as a purchase in an open-market or private transaction, coded as a "P" transaction, with 4,000 Palvella Therapeutics common shares acquired and no reported sales in this particular insider filing.